NASDAQ:KPTI • US48576U2050
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KARYOPHARM THERAPEUTICS INC (KPTI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-10 | Rodman & Renshaw | Initiate | Buy |
| 2026-02-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-05 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-11-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-13 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-10-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-09 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-08-12 | Baird | Maintains | Outperform -> Outperform |
| 2025-07-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-13 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-20 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-02-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-10 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-07 | Baird | Maintains | Outperform -> Outperform |
| 2024-08-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 146.033M -7.04% | 145.237M -0.55% | 146.067M 0.57% | 141.67M -3.01% | 207.72M 46.62% | 309.37M 48.94% | 642.28M 107.61% | 698.44M 8.74% | 789.31M 13.01% | 846.27M 7.22% | 806.83M -4.66% | |
| EBITDA YoY % growth | -129.01M 8.88% | -119.103M 7.68% | -90.411M 24.09% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -129.54M 8.90% | -119.443M 7.79% | -90.707M 24.06% | -99.585M -9.79% | -77.699M 21.98% | 83.699M 207.72% | 261.67M 212.63% | 396.46M 51.51% | 475.92M 20.04% | 523.88M 10.08% | 494.06M -5.69% | |
| Operating Margin | -88.71% | -82.24% | -62.10% | -70.29% | -37.41% | 27.05% | 40.74% | 56.76% | 60.30% | 61.90% | 61.23% | |
| EPS YoY % growth | -18.75 38.42% | -10.05 46.40% | -13.13 -30.65% | -5.16 60.72% | -4.48 13.13% | -0.96 78.68% | 1.31 236.65% | 3.08 135.94% | 4.61 49.67% | 5.49 19.03% | 6.20 13.01% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.33 51.97% | -1.15 73.39% | -1.55 59.32% | -1.53 31.23% |
| Revenue Q2Q % growth | 32.4M 7.95% | 35.866M -5.44% | 36.741M -16.58% | 37.635M 10.43% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.745M 31.61% | -22.36M 8.31% | -26.083M -71.37% | -26.045M -45.96% |
All data in USD
13 analysts have analysed KPTI and the average price target is 15.71 USD. This implies a price increase of 100.1% is expected in the next year compared to the current price of 7.85.
KARYOPHARM THERAPEUTICS INC (KPTI) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of KARYOPHARM THERAPEUTICS INC (KPTI) is -1.33 USD and the consensus revenue estimate is 32.40M USD.
The expected long term growth rate for KARYOPHARM THERAPEUTICS INC (KPTI) is 27.28%.